[Clinical testing of bronchospasmolytics in combined alternating test schedules]

Abstract

NAB 365, a new beta2-adrenergic bronchodilator was tested in oral doses of 0.01, 0.02, 0.03 and 0.04 mg. An acute trial was carried out in outpatients suffering from chronic obstructive airways disease. Airway resistance was measured by bodyplethysmography. For doses from 0.02 to 0.04 mg NAB 365 a quick, dose related and statistically significant bronchodliation without remarkable side effects could be found. The application of Fenoterol and Sch 1000 (ipratropiumbromide) by a metered dose inhaler was followed by a further and finally equal bronchodilation. To avoid adrenergic side effects the combination of NAB 365 with Sch 1000 should be preferred to the combination of NAB 365 with Fenoterol.